Hansa Medical is a research company focused on development of biopharmaceuticals and diagnostics within inflammation.

At present, Hansa Medical runs two preclinical biopharmaceutical programs: anti-alpha-11 for the treatment of rheumatoid arthritis and IdeS for treatment in connection with organ transplantation. Also, the company develops a clinical-stage diagnostic method, HMD-301, for the prognosis and diagnosis of severe sepsis.

Biopharma and diagnostics development at Hansa Medical is based on two different medical research fields: the molecular interplay between the immune system and pathogenic bacteria and research on a cell type called activated synovial fibroblasts